Treatment options for CLL patients with double-refractory disease after exposure to both inhibitors of BTK and BCL2 remain an unmet medical need with currently approved agents usually facilitating only short-lived remissions and patients are strongly encouraged to engage in prospective clinical trials investigating novel drugs. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.